Pearson/health claims forum
This article was originally published in The Tan Sheet
Executive Summary
FDA will hold a public meeting April 4 to solicit input on two dietary supplement labeling issues: implementation of the Pearson v. Shalala decision and whether claims about an effect on an existing disease should constitute a health claim or subject the product to drug regulation. In a March 3 letter to the dietary supplement community, FDA says a Federal Register notice detailing specific issues, logistics and registration information will be published shortly. Implementation of the Pearson vs. Shalala decision and development of a policy on disease-related statements are among CFSAN's "A-list" priorities for 2000 (1"The Tan Sheet" Feb. 14, p. 12)
You may also be interested in...
Health Claims Based On Varying Levels Of Evidence Need Distinctions - FDA
An issue FDA aims to address at the April 4 public meeting on implementation of the Pearson v. Shalala court decision is how best to convey to consumers that certain dietary supplement health claims do not have as much scientific support as other claims.
Health Claims Based On Varying Levels Of Evidence Need Distinctions - FDA
An issue FDA aims to address at the April 4 public meeting on implementation of the Pearson v. Shalala court decision is how best to convey to consumers that certain dietary supplement health claims do not have as much scientific support as other claims.
Health Claims Based On Varying Levels Of Evidence Need Distinctions - FDA
An issue FDA aims to address at the April 4 public meeting on implementation of the Pearson v. Shalala court decision is how best to convey to consumers that certain dietary supplement health claims do not have as much scientific support as other claims.